Kondratyuk M. O., Radchenko O. M.

CARDIO-RENAL-METABOLIC SYNDROME CHARACTERISTICS IN PATIENTS WITH CHRONIC FORMS OF ISCHEMIC HEART DISEASECARDIO-RENAL-METABOLIC SYNDROME CHARACTERISTICS IN PATIENTS WITH CHRONIC FORMS OF ISCHEMIC HEART DISEASE

---

Show/Download

About the author:

Kondratyuk M. O., Radchenko O. M.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

Cardio-renal metabolic syndrome (CRMs) is believed to be a holistic, systemic disorder with multiorgan dysfunction and a high number of adverse cardiovascular outcomes. It involves complex interconnection mechanisms between renal dysfunction, cardiovascular disease and metabolic disorders. Our study's feasibility was determined by several unresolved issues regarding the peculiarities of the course of CRMs. A deep understanding of the interrelationships of these conditions requires a comprehensive approach aimed at studying and evaluating risk factors and pathophysiological mechanisms. Studying the features of CRMs will allow optimising lifestyle, involving an interdisciplinary team in treatment and, in the future, developing a unified protocol for the management of such patients. The study aimed to evaluate the clinical manifestations and characteristics of CRMs in patients with chronic coronary heart disease. For this purpose, 113 patients with chronic coronary heart disease (CHD) were examined, chronic heart failure (CHF) I-III functional class (FC) according to the NYHA, who were diagnosed with CRMS according to the criteria: diagnosed CHD with CHF; body mass index (BMI) > 25 kg/m2; fasting glucose level > 6.1 mmol/l or previously diagnosed type 1 or type 2 diabetes mellitus (T2D) or use of hypoglycaemic therapy; glomerular filtration rate (GFR) < 80 kg/mkmol; blood creatinine above normal. The results of the study indicate that 15.92% of patients with chronic coronary artery disease can be diagnosed with complete cardio-renal metabolic syndrome. Patients with complete CRMs were younger but had higher BMI, systolic hypertension and tachycardia, hyperlipidemia and leptin resistance, higher levels of total fibrinogen and leukocytes, leukocyte intoxication index, lipid ratios and triglycerides. The deterioration of metabolic parameters was accompanied by activation of inflammation and endogenous intoxication, cytolysis and an increase in leptin.

Tags:

Bibliography:

1. Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, et al. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association Circulation. 2023;148(20):1636-1664. DOI: 10.1161/CIR.0000000000001186.
2. Roth S, M’Pembele R, Matute P, Kotfis K, Larmann J, Lurati Buse G. Cardiovascular-Kidney-Metabolic Syndrome: Association with Adverse Events After Major Noncardiac Surgery. Anesth Analg. 2024;139(3):679-681. DOI: 10.1213/ANE.0000000000006975.
3. Li W, Shen C, Kong W, Zhou X, Fan H, Zhang Y, et al. Association between the triglyceride glucose-body mass index and future cardiovascular disease risk in a population with Cardiovascular-Kidney-Metabolic syndrome stage 0-3: a nationwide prospective cohort study. Cardiovasc Diabetol. 2024;23(1):292. DOI: 10.1186/s12933-024-02352-6.
4. Kadowaki T, Maegawa H, Watada H, Yabe D, Node K, Murohara T, et al. Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan Diabetes Obes Metab. 2022;24(12):2283-2296. DOI: 10.1111/dom.14829.
5. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistanse.Diabetologia. 2003;46:1594-1603.
6. Radchenko O, Filipyuk A, redactory. Integralni hematolohochni indexy u diagnostyci ta prognozuvanni perebigu vnutrishnih hvorob. Lviv: Prostir – M; 2021. 127 s. [in Ukrainian].
7. Powell-Wiley TM, Poirier P, Burke LE, Despres JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143:e984–e1010. DOI: 10.1161/CIR.000000000000097.
8. Sebastian SA, Padda I, Johal G. Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review. Curr Probl Cardiol. 2024;49(2):102344. DOI: 10.1016/j.cpcardiol.2023.102344.
9. Tain YL, Hsu CN. The Renin-Angiotensin System and Cardiovascular-Kidney-Metabolic Syndrome: Focus on Early-Life Programming. Int J Mol Sci. 2024;25(6):3298. DOI: 10.3390/ijms25063298.
10. Kittelson KS, Junior AG, Fillmore N, da Silva Gomes R. Cardiovascular-kidney-metabolic syndrome – An integrative review. Prog Cardiovasc Dis. 2024;87:26-36. DOI: 10.1016/j.pcad.2024.10.012.
11. Keller MP, O’Connor C, Bitzer M, Schueler KL, Stapleton DS, Emfinger CH, et al. Genetic Analysis of Obesity-Induced Diabetic Nephropathy in BTBR Mice. Diabetes. 2024;73(2):312-317. DOI: 10.2337/db23-0444.
12. Panchyshyn MV, Panchyshyn YM. Hypocholesterolemiata vnutrishni hvoroby. Lviv: Liga-Pres; 2008. 336 s. [in Ukrainian].
13. Tanaka M, Sato T, Endo K, Inyaku M, Mori K, Hosaka I, et al. An increase in calculated small dense low-density lipoprotein cholesterol predicts new onset of hypertension in a Japanese cohort. Hypertens Res. 2023;46(12):2635-2645. DOI: 10.1038/s41440-023-01392-x.
14. Sniderman AD, Dufresne L, Pencina KM, Bilgic S, Thanassoulis G, Pencina MJ. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. Eur Heart J. 2024;45(27):2410-2418. DOI: 10.1093/eurheartj/ ehae258.
15. Zhu X, Chen Y, Zhu M, Hu J. The Relationship Between Small Dense Low-Density Lipoprotein Cholesterol and Metabolic Syndrome. Diabetes Metab Syndr Obes. 2024;17:1523-1532. DOI: 10.2147/DMSO.S450783.
16. Hirano T. Excess Triglycerides in Very Low-Density Lipoprotein (VLDL) Estimated from VLDL-Cholesterol could be a Useful Biomarker of Metabolic Dysfunction Associated Steatotic Liver Disease in Patients with Type 2 Diabetes. J Atheroscler Thromb. 2024;32(2):253-264. DOI: 10.5551/jat.65164.
17. D’Elia JA, Weinrauch LA. Lipid Toxicity in the Cardiovascular-Kidney-Metabolic Syndrome (CKMS). Biomedicines. 2024;12(5):978. DOI: 10.3390/biomedicines12050978.
18. Simsir IY, Sengoz Coskun NS, Akcay YY, Cetinkalp S. The Relationship Between Blood Hypoxia-Inducible Factor-1alpha, Fetuin-A, Fibrinogen, Homocysteine, and Amputation Level. Int J Low Extrem Wounds. 2022;21(4):405-413. DOI: 10.1177/1534734620948342.
19. Nimmala SG, Gokhale VS, Yadav P, Mangudkar S, Malik S. A Study of the Mean Platelet Volume and Plasma Fibrinogen in Type Two Diabetes Mellitus Patients Versus Healthy Controls and Their Role as Early Markers of Diabetic Microvascular Complications. Cureus. 2024;16(7):e65458. DOI: 10.7759/cureus.65458.
20. Khanam A, Alouffi S, Alyahyawi AR, Husain A, Khan S, Alharazi T, et al. Generation of autoantibodies against glycated fibrinogen: Role in diabetic nephropathy and retinopathy. Anal Biochem. 2024;685:115393. DOI: 10.1016/j.ab.2023.115393.

Publication of the article:

«Bulletin of problems biology and medicine», 2025 Issue 1, 176, 211-218 pages, index UDC 616.12-005.4-036.12-06:(616.12+616.61+616-056.5)]-008

DOI:

10.29254/2077-4214-2025-1-176-211-218